Walleye Capital LLC Makes New Investment in Rezolute, Inc. (NASDAQ:RZLT)

Walleye Capital LLC bought a new position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 491,466 shares of the company's stock, valued at approximately $2,408,000. Walleye Capital LLC owned approximately 0.85% of Rezolute at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of RZLT. Geode Capital Management LLC increased its stake in shares of Rezolute by 5.2% in the fourth quarter. Geode Capital Management LLC now owns 517,014 shares of the company's stock valued at $2,535,000 after buying an additional 25,413 shares during the period. Exome Asset Management LLC increased its stake in shares of Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company's stock valued at $1,707,000 after buying an additional 69,656 shares during the period. State Street Corp increased its position in Rezolute by 11.6% during the 3rd quarter. State Street Corp now owns 125,472 shares of the company's stock valued at $609,000 after purchasing an additional 13,000 shares during the period. American Century Companies Inc. increased its position in Rezolute by 62.1% during the 4th quarter. American Century Companies Inc. now owns 64,591 shares of the company's stock valued at $316,000 after purchasing an additional 24,742 shares during the period. Finally, Barclays PLC acquired a new stake in Rezolute during the 4th quarter valued at approximately $314,000. Institutional investors and hedge funds own 82.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $14.00 target price on shares of Rezolute in a research report on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. JMP Securities increased their target price on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. Finally, Guggenheim reissued a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Rezolute has a consensus rating of "Buy" and an average price target of $26.43.

Insider Buying and Selling

In other news, CFO Daron Evans acquired 10,000 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 237,900 shares in the company, valued at approximately $687,531. This represents a 4.39 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Nevan C. Elam bought 12,302 shares of the business's stock in a transaction dated Thursday, March 27th. The stock was acquired at an average price of $2.85 per share, for a total transaction of $35,060.70. Following the purchase, the chief executive officer now directly owns 224,119 shares in the company, valued at approximately $638,739.15. The trade was a 5.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 39,060 shares of company stock worth $130,694 in the last quarter. Insiders own 18.39% of the company's stock.

Rezolute Stock Performance

Shares of NASDAQ RZLT traded down $0.09 during trading on Thursday, hitting $3.88. 1,186,640 shares of the company traded hands, compared to its average volume of 582,180. The business's fifty day moving average is $3.39 and its 200 day moving average is $4.46. Rezolute, Inc. has a fifty-two week low of $2.22 and a fifty-two week high of $6.19. The firm has a market capitalization of $234.88 million, a price-to-earnings ratio of -3.20 and a beta of 0.97.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. On average, analysts predict that Rezolute, Inc. will post -0.93 EPS for the current year.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.